ESP-01: Phase Ib/IIa started

Esperas began an open-label, Canadian Phase Ib/IIa trial to evaluate 10-200 mg oral

Read the full 135 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE